KEYMED BIO-B

2162
69.0001.22% ( -0.850 )
Delay Closed: Nov 16, 16:08:11

Overview

KEYMED BIO-B (2162)

Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic ar...

Open
69.550
High
70.950
Low
68.150
Prev. Close
69.850
Volume
2.00M
Turnover
138.22M
Avg Price
69.048
Bid/Ask Ratio
-80.00%
Amplitude
4.01%
52wk High
89.750
Volume Ratio
0.70
Turnover Ratio
0.67%
52wk Low
44.660
HK Mkt Cap
20.61B
Market CapHKD
20.61B
P/ETTM
23.14
P/EDynamic
7.35
P/EStatic
--
EPSTTM
2.98
EPSDynamic
9.38
EPSStatic
--
BVPS
15.44
P/B
4.47
HK Shares
298.74M
Dividend YieldTTM
--
DividendTTM
--
Shares
298.74M
Min lot size
500
Currency
HKD

KEYMED BIO-B Analyst Rating

View more

Forecast & Rating

Nov 6, 2026
Price forecast
HK$105.6553.11%
Forecast & RatingStrong buy
17analysts
  • Strong buy64.71%
  • Buy35.29%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Nov, 9

    JPMorgan initiated coverage with an Overweight rating and a HK$95 target price, and with Stapokibart (CM310) product revenue up 227% year-on-year in the first three quarters, KEYMED BIO-B opened 0.9% lower, probed a low and rebounded, spiking to HK$74.45 at 09:56 BJ before fading through the afternoon to close at HK$73.00, up 5.3% from the prior close of HK$69.30 on HK$196 million turnover. Broad strength in innovative-drug names provided the backdrop; second-quarter revenue of HK$356 million rose 30.4% year-on-year and net profit of HK$703 million rose more than 17-fold, a 197% net margin, though operating loss remained at HK$111 million, 40.9% wider, indicating profit leans on non-operating items. The price sits below MA20 of 74.47 and MA60 of 76.33, 19.1% under the 52-week high of HK$89.75, up 35.8% year-to-date at a 24.35x P/E. Still, China Universal earlier cut 991,000 shares at about HK$70.9, leaving shareholder selling and sentiment after clinical data disclosures worth watching.

  2. Nov, 4

    Keymed Biosciences (2162.HK) reversed early weakness to close at HK$68.90, up 8.59%, having opened at HK$62.45 and touched an intraday low of HK$63.20 in the morning session; the afternoon session carried it to HK$68.55 by 14:56 BJ on HK$274 million turnover and a 1.39% turnover rate, as sentiment across innovative-drug names recovered after the CLARITY-Gastric 01 data-driven selloff. Q2 2026 revenue rose 30.41% yoy to HK$356.4 million and net profit reached HK$703.1 million (EPS HK$2.4545), though operating profit stayed negative at -HK$110.6 million, leaving the 197.3% net margin reliant on non-operating items. The stock is up 28.91% YTD but remains 23.23% below its 52-week high of HK$89.75 and trades under both MA20 (HK$75.42) and MA60 (HK$76.83), with PB at 4.46 and PE at 23.11. China Universal Asset Management trimmed 991,000 shares at about HK$70.9, keeping overhead supply in view.

  3. Nov, 3

    KEYMED BIO-B fell 4.8% to HK$63.35, reversing from HK$68.95 and touching HK$62.65 intraday, as the global Phase III data release for CLDN18.2 ADC CMG901 and cautious read-across to CLARITY-Gastric 01 weighed on sentiment; CLSA also flagged weak mood, while innovative-drug concept stocks broadly declined. China Universal Asset Management cut 991,000 shares at about HK$70.9, adding supply pressure. Fundamentals remain mixed: Q2 revenue rose 30.4% yoy to HK$356.4 million and net profit jumped 1,727.7% to HK$703.1 million, yet operating profit stayed negative at HK$110.6 million. At HK$63.35 the stock sits 29.4% below its 52-week high of HK$89.75, 41.9% above the HK$44.66 low, below both MA20 of HK$75.98 and MA60 of HK$77.06, with YTD gain trimmed to 18.5%. Though the company plans to buy shares under its 2022 restricted share unit plan.

  4. Oct, 27

    Keymed Biosciences (2162.HK) closed down 14.8% at HK$69.00 after global Phase III data for its CLDN18.2 ADC CMG901 triggered selling, with the broader Hong Kong-listed biotech cohort also declining. The stock opened at HK$83.45, faded through the morning and touched HK$68.00 at 13:41 BJ, on HK$747 million turnover and a 3.53% turnover rate. The contrast with reported fundamentals is stark: Q2 2026 revenue rose 30.41% year on year to HK$356 million and net profit reached HK$703 million, yet operating profit remained a HK$111 million loss. At HK$69.00 the shares sit below the MA20 of HK$78.94 and MA60 of HK$77.99, 23.12% below the 52-week high of HK$89.75, while still up 29.09% year to date; the PE is 23.14 and PB 4.47. CICC lifted its target price to HK$110.0 from HK$98.0, a 12.24% increase, though China Universal Asset Management added 242,000 shares at about HK$87.96, a positioning move that contrasts with today's weak tape.

  5. Oct, 23

    KEYMED BIO-B opened lower, probed a morning-session low of HK$76.85 and recovered to close up 3.22% at HK$81.65 on HK$198 million turnover, tracking the approval of Kanyueda (CM310) for adolescent atopic dermatitis, revenue for that product more than doubling and continuing to benefit from national reimbursement, plus the selection of self-developed CDH17 ADC CM518D1 clinical data at ESMO. The stock climbed to HK$83.30 by 14:20 BJ before easing into the close. Q2 2026 revenue rose 30.41% year on year to HK$356.4 million, with net profit of HK$703.1 million and ROE of 60.79%. CICC raised its target price by 12.24% to HK$110 while maintaining its rating. The shares are up 52.76% year to date and sit above the MA20 of 78.87 and MA60 of 77.92, still 9.03% below the 52-week high of HK$89.75; operating income, though, remains negative at -HK$110.6 million.

News

Bullish vs. Bearish — Last 3 Months

3.3k followers · 0 opinions
▲Bullish50%
50%Bearish▼